Advertisement
The PLoS Medicine Debate

The PLoS Medicine Debate The PLOS Medicine Debate discusses important but controversial issues in clinical practice, public health policy, or health in general. Debates will be commissioned from two or more authors with differing points of view.

See all article types »

Should an Institution That Has Commercial Rights in a New Drug or Device Be Allowed to Evaluate the Technology?

  • Ross McKinney,
  • David Korn
  • Published: January 25, 2005
  • DOI: 10.1371/journal.pmed.0020009

Reader Comments (1)

Post a new comment on this article

It depends of the goal

Posted by plosmedicine on 30 Mar 2009 at 23:40 GMT

Author: Pedro Urra
Position: Director
Institution: Infomed www.sld.cu
E-mail: pedro.urra@infomed.sld.cu
Submitted Date: February 19, 2005
Published Date: February 23, 2005
This comment was originally posted as a “Reader Response” on the publication date indicated above. All Reader Responses are now available as comments.

I beleive that the technical evaluation of a New Drug or Device for acceptance must be done by an independent institution with a public mandate. Any institution that can help with the evaluation could participate in it althought it has commercial rights. The way it participates must be clearly established and must conducted considering the policies and principles that guarantee the objective evaluation. It is quite simple to exclude or include by general considerations. What is obvius is that the technical evaluation can not be conducted by such institutions and that they must participate in the way defined by procedures and clear agreements.

Competing interests declared: I do not have any competing interest.